Discovery and synthesis of [6-hydroxy-3-[4-[2-(1- piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]benzo[b]thiophene: A novel, highly potent, selective estrogen receptor modulator

Journal of Medicinal Chemistry

Volumn 40, Issue 10, 1997, Pages 1407-1417

  Palkowitz, Alan D ^a   Glasebrook, Andrew L ^a   Thrasher, K Jeff ^a   Hauser, Kenneth L ^a   Short, Lorri L ^a   Phillips, D Lynn ^a   Muehl, Brian S ^a   Sato, Masahiko ^a   Shetler, Pamela K ^a   Cullinan, George J ^a   Pell, Tina R ^a   Bryant, Henry U ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 HYDROXY 3 [4 [2 (1 PIPERIDINYL)ETHOXY]PHENOXY] 2 (4 HYDROXYPHENYL)BENZO[B]THIOPHENE; ANTIESTROGEN; BENZOTHIOPHENE DERIVATIVE; CHOLESTEROL; ESTROGEN; ESTROGEN RECEPTOR; FULVESTRANT; LIPID; OXYGEN; RALOXIFENE; TAMOXIFEN; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BINDING COMPETITION; BONE; BONE MINERAL; BREAST; CELL PROLIFERATION; CONTROLLED STUDY; DRUG BINDING; DRUG EFFICACY; DRUG POTENCY; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; NONHUMAN; ORAL DRUG ADMINISTRATION; OVARIECTOMY; RAT; STRUCTURE ACTIVITY RELATION; SUBCUTANEOUS DRUG ADMINISTRATION; UTERUS;

ANIMALS; BREAST NEOPLASMS; CELL DIVISION; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MOLECULAR STRUCTURE; PIPERIDINES; RALOXIFENE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ESTROGEN; TUMOR CELLS, CULTURED;

EID: 0003630405     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970167b     Document Type: Article

References (39)

1. Grese, T. A.; Dodge, J. A. Estrogen receptor modulators: effects in non-traditional target tissues. In Annual Reports in Medicinal Chemistry; Bristol, J. A., Ed.; Academic Press: New York, 1996; Vol. 31, pp 181-190.
2. (a) McDonnell, D. P.; Clemm, D. L.; Hermann, T.; Goldman, M. E.; Pike, J. W. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol. Endocrinol. 1995, 9, 659-669.
3. (b) Kauffman, R. F.; Bryant, H. U. Selective estrogen receptor modulators. Drug News Perspect. 1995, 8, 531-539.
4. (c) Sato, M.; Rippy, M. K.; Bryant, H. U. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J. 1996, 10, 905-912.
5. (a) Wakeling, A. E.; Dukes, M.; Bowler, J. A potent specific pure antiestrogen with clinical potential. Cancer Res. 1991, 51, 3867-3873.
6. (b) Gallagher A.; Chambers, T. J.; Tobias, J. H. The estrogen antagonist ICI 182780 reduces cancellous bone volume in female rats. Endocrinology 1993, 133, 835-842.
7. (c) Bryant, H. U.; Wilson, P. K.; Adrian, M. D.; Cole, H. W.; Phillips, D. L.; Dodge, J. A.; Grese, T. A.; Sluka, J. P.; Glasebrook, A. L. Selective estrogen receptor modulators: pharmacological profile in the rat uterus. J. Soc. Gynecol. Invest. 1998, 3, 152A.
8. (a) Black, L. J.; Sato, M.; Rowley, E. R.; Magee, D. E.; Bekele, A.; Williams, D. C.; Cullinan, G. J.; Bendele, R.; Kauffmann, R. F.; Bensch, W. R.; Frolik, C. A.; Termine, J. D.; Bryant, H. U. Raloxifene (LY139481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin. Invest. 1994, 93, 63-69.
9. (b) Draper, M. W.; Flowers, D. E.; Huster, W. J.; Nield, J. A.; Harper, K. D.; Arnaud, C. A controlled trial of raloxifene (LY139481 HCl): Impact on bone turnover and serum lipid profile in healthy postmenopausal women. J. Bone Mineral Res. 1996, 11, 835-842.
10. (c) Jordan, V. C.; Allen, K. E.; Dix, C. J. Pharmacology of tamoxifen in laboratory animals. Cancer Treat. Rep. 1980, 64, 745-759.
11. (d) Jordan, V. C. A current view of tamoxifen for the treatment and prevention of breast cancer. Br. J. Pharmacol. 1993, 110, 507-517.
12. (e) Lindsay, R. Sex steroids in the pathogenesis and prevention of osteoporosis. In Osteoporosis: Etiology, Diagnosis, and Management; Riggs, B. L., Melton, L. J., Eds.; Raven: New York, 1988; pp 333-358.
13. (f) Ciocca, D. R.; Vargas Roig, L. M. Estrogen receptors in human nontarget tissues: biological and clinical implications. Endocr. Rev. 1995, 16, 35-62.
14. (g) Session, D. R.; Kelley, A. C.; Jewelewicz, R. Current concepts in estrogen replacement therapy in the menopause. Fertility Sterility 1993, 2, 277-284.
15. (h) Colditz, G. A.; Hankinson, S. E.; Hunter, D. J.; Willett, W. C.; Manson, J. E.; Stampfer, M. J.; Hennekens, C.; Rosner, B.; Speizer, F. E. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N. Engl. J. Med. 1995, 332, 1589-1593.
16. (i) Porter, K. B.; Tsibris, J. C. M.; Porter, G. W.; Fuchs-Young, R.; O'Brien, W. F.; Knadler, M. P.; Spellacy, W. N. Raloxifene causes rapid regression of abdominal wall leiomyomas in the estrogen-induced guinea pig model. J, Soc. Gynecol. Invest. 1996, 3, 147A.
17. Clemens, J. A.; Bennett, D. R.; Black, L. J.; Jones, C. D. Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors on LH and prolactin levels. Life Sci. 1983, 32, 2869-2875.
18. Katzenellenbogen, J. A.; O'Malley, B. W.; Katzenellenbogen, B. S. Tripartite steroid hormone receptor pharmacology: Interaction with multiple effector sites as basis for the cell- and promoter-specific action of these hormones. Mol. Endocrinol. 1996, 10, 119-131.
19. (a) Knabbe, C.; Lippman, M. E.; Wakefield, L. M.; Flanders, K. C.; Kasid, A.; Derynck, R.; Dickon, R. B. Evidence that transforming growth facotr-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell 1987, 48, 417-428.
20. (b) Colletta, A. A.; Wakefield, L. M.; Howell, F. V.; van Roozendaal, K. E. P.; Danielpour, D.; Ebbs, S. R.; Sporn, M. B.; Baum, M. Anti-estrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts. Br. J. Cancer 1990, 62, 405-409.
21. (c) Yang, N. N.; Bryant, H. U.; Hardikar, S.; Sato, M.; Galvin, R.; Glasebrook, A. L. Estrogen and raloxifene stimulate transforming growth factor beta-3 (TGF-b3) gene expression in rat bone: a potential mechanism for estrogen and raloxifene mediated bone maintenance. Endocrinology 1996, 137, 2075-2081.
22. Yang, N. N.; Venugopalan, M.; Hardikar, S.; Glasebrook, A. L. Identification of an estrogen response element activated by metabolites of 17-β estradiol and raloxifene. Science 1996, 273, 1222-1225.
23. (a) Jones, C. D.; Jevnikar, M. G.; Pike, A. J.; Peters, M. K.; Black, L. J.; Thompson, A. R.; Falcone, J. F.; Clemens, J. A. Antiestrogens. 2. Structure-activity studies in a sereis of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiene-3-yl][4-[2-(1-piperidinyl)-ethoxy] phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity. J. Med. Chem. 1984, 27, 1057-1066.
24. (b) Grese, T. A.; Cho, S.; Finely, D. R.; Godfrey, A. G.; Jones, C. D.; Lugar, C. W., III; Martin, M. J.; Matsumoto, K.; Pennington, L. D.; Winter, M. A.; Adrian, M. D.; Cole, H. W.; Magee, D. E.; Phillips, D. L.; Rowley, E. R.; Short, L. L.; Glasebrook, A. L.; Bryant, H. U. Structure-activity relationships of selective estrogen receptor modulators (SERMs). Modifications to the 2-arylbenzothiophene core of raloxifene. J. Med. Chem., in press.
25. Jones, C. D.; Suarez, T. 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents. U.S. Patent 4,133,814.
26. Venier, C. G.; Squires, T. G.; Chen, Y.; Hussmann, G. P.; Shei, J. C.; Smith, B. F. Peroxytriflouroacetic acid. A convenient reagent for the preparation of sulfoxides and sulfones. J. Org. Chem. 1982, 47, 3773-3774.
27. 2, 10% Pd/C, EtOH/EtOAc).
28. (b) Yield of 9a is overall from hydroxyphenyl disulfide.
29. Brown, H. C.; Weissman, P. M.; Min-Yoon, N. Selective reductions IX. Reactions of lithium aluminum hydride with selected organic compounds containing representative functional groups. J. Am. Chem. Soc. 1966, 88, 1458-1463.
30. Miller, R. B.; Moock, T. A general synthesis of 6-H-pyrido[4,3-b]carbazole alkaloides. Tetrahedron Lett. 1980, 21, 3319-3322 and references cited therein.
31. (a) Scholl, S. M.; Huff, K. K.; Lippman, M. E. Antiestrogenic effects of LY117018 in MCF-7 cells. Endocrinology 1983, 113, 611-617.
32. (b) Miller, M. A.; Katzenellenbogen, B. S. Characterization and quantitation of antiestrogen binding sites in estrogen receptor-positive and-negative human breast cancer cell lines. Cancer Res. 1983, 43, 3094-3100.
33. (c) Thompson, E. W.; Reich, R.; Shima, T. B.; Albini, A.; Graf, J.; Martin, G. R.; Dickson, R. B.; Lippman, M. E. Differential growth and invasiveness of MCF-7 breast cancer cells by antiestrogens. Cancer Res. 1988, 48, 6764-6768.
34. Black, L. J.; Jones, C. D.; Falcone, J. F. Antagonism of estrogen action with a new benzothiophene derived antiestrogen. Life Sci. 1983, 32, 1031-1036.
35. (a) Sato, M.; Kim, J.; Short, L. L.; Slemenda, C. W.; Bryant, H. U. Longitudinal and cross-sectional analysis of raloxifene effects on tibae from ovariectomized aged rats. J. Pharmacol. Exp. Ther. 1995, 272, 1252-1259.
36. (b) Bryant, H. U.; Bendele, A. M.; Magee, D. E.; Cole, H. W.; Spaethe, S. W. Pharmacologic profile of estrogen induced uterine eosinophilia in the ovariectomized (OVX) rat. Pharmacologist 1992, 34, 194.
37. Tamoxifen was purchased from Sigma Chemical Co., St. Louis, MO. 4-Hydroxytamoxifen was prepared at Lilly Research Laboratories according to procedures described in Robertson, D. W.; Katzenellenbogen, J. A. J. Org. Chem. 1982, 47, 2387-2393. ICI 182,780 was prepared at Lilly Research Laboratories according to the procedures described in Bowler, J.; Tait, B. S. U.S. Patent 4,659,516.
38. Tamoxifen was purchased from Sigma Chemical Co., St. Louis, MO. 4-Hydroxytamoxifen was prepared at Lilly Research Laboratories according to procedures described in Robertson, D. W.; Katzenellenbogen, J. A. J. Org. Chem. 1982, 47, 2387-2393. ICI 182,780 was prepared at Lilly Research Laboratories according to the procedures described in Bowler, J.; Tait, B. S. U.S. Patent 4,659,516.
39. Grese, T. A.; Sluka, J. P.; Bryant, H. U.; Cole, H. W.; Kim, J. R.; Magee, D. E.; Rowley, E. R.; Sato, M. Benzopyran selective estrogen receptor modulators (SERMs): Pharmacological effects and structural correlation with raloxifene. Bioorg. Med. Chem. Lett. 1996, 6, 903-908.